Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial

Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial

Background: Respiratory syncytial virus (RSV) is responsible for most respiratory tract infections and hospitalizations in infants and represents a significant economic burden for public health. The development of a safe, effective, and affordable vaccine is a priority for the WHO. Methods: We condu...

Full description

Bibliographic Details
Main Authors: Katia Abarca, Emma Rey-Jurado, Natalia Muñoz-Durango, Yaneisi Vázquez, Jorge A. Soto, Nicolás M.S. Gálvez, Javier Valdés-Ferrada, Carolina Iturriaga, Marcela Urzúa, Arturo Borzutzky, Jaime Cerda, Luis Villarroel, Victoria Madrid, Pablo A. González, José V. González-Aramundiz, Susan M. Bueno, Alexis M. Kalergis
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:EClinicalMedicine
Subjects:
Human respiratory syncytial virus
BCG vaccine
Phase I clinical trial
Safety
Transmissibility
Immunogenicity
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537020302613

Internet

http://www.sciencedirect.com/science/article/pii/S2589537020302613

Similar Items